{"cluster": 36, "subcluster": 31, "abstract_summ": "Notably, while a rapid and well-coordinated immune response represents the first line of defense against viral infection, excessive inflammatory innate response and impaired adaptive host immune defense may lead to tissue damage both at the site of virus entry and at systemic level.Understanding immune evasion strategies of SARS-CoV2 and the resulting delayed massive immune response will result in the identification of biomarkers that predict outcomes as well as phenotype and disease stage specific treatments that will likely include both antiviral and immune modulating agents.Therefore, a dampened innate anti-viral immune response seems to be the primary cause of the delayed critical cascade of uncontrolled immune events leading to fulminating systemic inflammation.Besides a direct impact on pathogens, modulation of the host immune system provides an additional facet to antiviral drug development because suitable immune modulation can boost innate defence mechanisms against the pathogens.The occurrence of virus transmission even in asymptomatic subjects infected with SARS-CoV-2 clearly strengthens the evidence for a key role of sufficient immune control of viral replication in a subset of cases (e.g. in children, a population with highly effective innate immune responses).", "title_summ": "Dysregulation of the immune system as a driver of the critical course of the novel coronavirus disease 2019.Tissue-specific tolerance in fatal Covid-19Mechanistic modeling of the SARS-CoV-2 and immune system interplay unravels design principles for diverse clinicopathological outcomesCOVID-19: Immunology and treatment optionsImmune modulation in COVID-19: Strategic considerations for personalized therapeutic interventionImmune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2Targeting innate immunity by blocking CD14: Novel approach to control inflammation and organ dysfunction in COVID-19 illnessHarnessing resolving\u2010based therapeutics to treat pulmonary viral infections: What can the future offer to COVID\u201019?Is macrophages heterogeneity important in determining COVID-19 lethality?Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophagesNatural antiviral compound silvestrol modulates human monocyte\u2010derived macrophages and dendritic cellsAltered cytokine levels and immune responses in patients with SARS-CoV-2 infection and related conditions", "title_abstract_phrases": "Notably, while a rapid and well-coordinated immune response represents the first line of defense against viral infection, excessive inflammatory innate response and impaired adaptive host immune defense may lead to tissue damage both at the site of virus entry and at systemic level.Understanding immune evasion strategies of SARS-CoV2 and the resulting delayed massive immune response will result in the identification of biomarkers that predict outcomes as well as phenotype and disease stage specific treatments that will likely include both antiviral and immune modulating agents.Therefore, a dampened innate anti-viral immune response seems to be the primary cause of the delayed critical cascade of uncontrolled immune events leading to fulminating systemic inflammation.Besides a direct impact on pathogens, modulation of the host immune system provides an additional facet to antiviral drug development because suitable immune modulation can boost innate defence mechanisms against the pathogens.The occurrence of virus transmission even in asymptomatic subjects infected with SARS-CoV-2 clearly strengthens the evidence for a key role of sufficient immune control of viral replication in a subset of cases (e.g. in children, a population with highly effective innate immune responses)."}